[go: up one dir, main page]

MX2018012797A - Inhibidores de erbb y usos de los mismos. - Google Patents

Inhibidores de erbb y usos de los mismos.

Info

Publication number
MX2018012797A
MX2018012797A MX2018012797A MX2018012797A MX2018012797A MX 2018012797 A MX2018012797 A MX 2018012797A MX 2018012797 A MX2018012797 A MX 2018012797A MX 2018012797 A MX2018012797 A MX 2018012797A MX 2018012797 A MX2018012797 A MX 2018012797A
Authority
MX
Mexico
Prior art keywords
erbb inhibitors
erbb
inhibitors
compositions
methods
Prior art date
Application number
MX2018012797A
Other languages
English (en)
Inventor
Novotny Christopher
Shen Weijun
M Shokat Kevan
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2018012797A publication Critical patent/MX2018012797A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Drilling Tools (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

En la presente, se describen, entre otros, composiciones de moduladores de ErbB y métodos para usarlas.
MX2018012797A 2016-04-19 2017-04-19 Inhibidores de erbb y usos de los mismos. MX2018012797A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662324864P 2016-04-19 2016-04-19
PCT/US2017/028437 WO2017184775A1 (en) 2016-04-19 2017-04-19 Erbb inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
MX2018012797A true MX2018012797A (es) 2020-01-09

Family

ID=60116344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012797A MX2018012797A (es) 2016-04-19 2017-04-19 Inhibidores de erbb y usos de los mismos.

Country Status (13)

Country Link
US (1) US20190119284A1 (es)
EP (1) EP3445768A4 (es)
JP (1) JP2019514869A (es)
CN (1) CN109952306A (es)
AU (1) AU2017253096A1 (es)
BR (1) BR112018071592A8 (es)
CA (1) CA3021324A1 (es)
EA (1) EA201892368A1 (es)
IL (1) IL262400A (es)
MX (1) MX2018012797A (es)
PH (1) PH12018502233A1 (es)
SG (1) SG11201809223PA (es)
WO (1) WO2017184775A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992573A1 (ru) 2017-04-28 2020-04-06 Сиэтл Дженетикс, Инк. Лечение her2-положительных злокачественных новообразований
CN112638899B (zh) * 2018-08-01 2023-09-05 上海轶诺药业有限公司 一类具有免疫调节功能的芳香化合物的制备和应用
PT3909584T (pt) * 2019-01-11 2024-01-12 Taiho Pharmaceutical Co Ltd Composto de pirimidina ou um seu sal
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
CN111303158A (zh) * 2020-04-09 2020-06-19 成都睿智化学研究有限公司 一种（4-氯-1H-吡唑啉[3,4-d]嘧啶-3-基）芳基甲酮的制备方法
KR20230031926A (ko) * 2020-07-15 2023-03-07 다이호야쿠힌고교 가부시키가이샤 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
ATE195123T1 (de) * 1995-04-03 2000-08-15 Novartis Erfind Verwalt Gmbh Pyrazolderivate und verfahren zu deren herstellung
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP4881875B2 (ja) * 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
CN101679313A (zh) * 2007-04-13 2010-03-24 休普基因公司 用于治疗癌症或过度增殖性疾病的axl激酶抑制剂
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CN102482281A (zh) * 2009-07-28 2012-05-30 宇部兴产株式会社 吡咯并[2，3-d]嘧啶衍生物
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN103570723B (zh) * 2012-07-27 2016-07-13 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物及其制备方法和在药物制备中的用途

Also Published As

Publication number Publication date
CN109952306A (zh) 2019-06-28
US20190119284A1 (en) 2019-04-25
SG11201809223PA (en) 2018-11-29
PH12018502233A1 (en) 2019-06-03
IL262400A (en) 2018-12-31
EP3445768A1 (en) 2019-02-27
AU2017253096A1 (en) 2018-11-08
BR112018071592A8 (pt) 2019-02-26
EP3445768A4 (en) 2019-12-18
BR112018071592A2 (pt) 2019-02-12
JP2019514869A (ja) 2019-06-06
WO2017184775A1 (en) 2017-10-26
CA3021324A1 (en) 2017-10-26
EA201892368A1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
ZA201906822B (en) Indole ahr inhibitors and uses thereof
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2019007020A (es) Anticuerpos il-11.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MY191581A (en) Anti-pd-1 antibodies
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2019007021A (es) Anticuerpos il-11ra.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
EP4361178A3 (en) Acid-alpha glucosidase variants and uses thereof
MY176855A (en) Anti-jagged1 antibodies and methods of use
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2019010984A (es) Composiciones de sintecina y metodos de uso.